切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2020, Vol. 09 ›› Issue (04) : 355 -362. doi: 10.3877/cma.j.issn.2095-3224.2020.04.006

所属专题: 文献

论著

老年与非老年直肠黏液腺癌患者对不同放疗策略的受益可能不同:一项基于SEER数据库的回顾性研究
刘恒昌1, 李春香2, 魏然1, 刘正1, 陈海鹏1, 关旭1, 赵志勋1, 姜争1,(), 王锡山1,()   
  1. 1. 100021 北京,国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院结直肠外科
    2. 100021 北京,国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院胸外科
  • 收稿日期:2020-03-28 出版日期:2020-08-25
  • 通信作者: 姜争, 王锡山
  • 基金资助:
    中国医学科学院医学与健康科技创新工程项目(No.2016-I2M-1-001); 北京市科技计划(No.D171100002617004)

Elderly and non-elderly patients with rectal mucinous adenocarcinoma may benefit from different radiotherapy strategies differently: a retrospective study based on SEER database

Hengchang Liu1, Chunxiang Li2, Ran Wei1, Zheng Liu1, Haipeng Chen1, Xu Guan1, Zhixun Zhao1, Zheng Jiang1,(), Xishan Wang1,()   

  1. 1. Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    2. Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
  • Received:2020-03-28 Published:2020-08-25
  • Corresponding author: Zheng Jiang, Xishan Wang
  • About author:
    Corresponding author: Wang Xishan, Email: ;
    Jiang Zheng, Email:
引用本文:

刘恒昌, 李春香, 魏然, 刘正, 陈海鹏, 关旭, 赵志勋, 姜争, 王锡山. 老年与非老年直肠黏液腺癌患者对不同放疗策略的受益可能不同:一项基于SEER数据库的回顾性研究[J]. 中华结直肠疾病电子杂志, 2020, 09(04): 355-362.

Hengchang Liu, Chunxiang Li, Ran Wei, Zheng Liu, Haipeng Chen, Xu Guan, Zhixun Zhao, Zheng Jiang, Xishan Wang. Elderly and non-elderly patients with rectal mucinous adenocarcinoma may benefit from different radiotherapy strategies differently: a retrospective study based on SEER database[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2020, 09(04): 355-362.

目的

探讨老年与非老年直肠黏液腺癌患者对于新辅助放疗、辅助放疗的受益情况,并分析影响直肠黏液腺癌患者预后的因素。

方法

应用美国国家癌症研究所的监测、流行病学和结果数据库(SEER),收集2000~2016年,病理诊断为直肠黏液腺癌的患者共3 997例,根据年龄分为老年组(≥60岁)和非老年组(<60岁),分析比较两组接受新辅助放疗联合手术、单纯手术和术后辅助放疗患者的预后情况,对两组患者的三种治疗方式分别进行倾向得分匹配,比较不同治疗方法对预后的影响,应用Kaplan-Meier法分别绘制生存曲线,应用Log-rank检验分析各组生存差异,应用COX比例风险模型分析影响直肠黏液腺癌患者预后的因素。

结果

三种治疗方案的总生存率,新辅助放疗总生存率最高,其次为术后放疗,最后为单纯手术组,组间比较差异有统计学意义(χ2=13.117,22.541;P<0.05)。但三种治疗方案的肿瘤特异性生存,仅新辅助放疗显著高于术后放疗(χ2=4.023,P=0.045)。对各种治疗方案进行倾向得分匹配后,老年患者新辅助放疗的总体生存率显著高于单纯手术(χ2=4.874,P=0.027),非老年患者单纯手术的总体生存率(χ2=5.530,P=0.019)和肿瘤特异性生存率(χ2=4.825,P=0.028)均显著高于术后放疗。高龄(≥60岁)、男性、未化疗和高TNM分期是直肠黏液腺癌患者总生存率较差的影响因素,其HR分别为1.689(95% CI=1.524~1.871)、1.110(95% CI=1.007~1.223)和1.549(95% CI=1.338~1.792),Ⅱ期HR=2.675(95% CI=1.191~6.008),Ⅲ期HR=3.617(95% CI=1.612~8.115),Ⅳ期HR=10.835(95% CI=4.797~24.474);高龄(≥60岁)、未化疗和高TNM分期是直肠黏液腺癌患者肿瘤特异性生存率较差的影响因素,其HR分别为1.297(95% CI=1.156~1.456),1.344(95% CI=1.129~1.601),Ⅲ期HR=6.365(95% CI=1.582~25.614),Ⅳ期HR=20.957(95% CI=5.189~84.637)。

结论

老年直肠黏液腺癌患者可能从新辅助放疗中获益,而对于非老年患者,放疗的预后并不优于单纯手术治疗。

Objective

To investigate the benefit of neoadjuvant radiotherapy and adjuvant radiotherapy in elderly and non-elderly patients with rectal mucinous adenocarcinoma, and to analyze the factors influencing the prognosis of patients with rectal mucinous adenocarcinoma.

Methods

Based on the Surveillance, Epidemiology, and End Result s database (SEER) of the National Cancer Institute of the United States, 3 997 patients with rectal mucinous adenocarcinoma diagnosed pathologically from 2000 to 2016 were collected. According to the patient′s age, the patients were divided into the elderly group (≥ 60 years old) and the non-elderly group (< 60 years old). The prognosis of the two groups was analyzed and compared. Three treatment methods of the two groups were matched by the propensity score matching method, and the influence of different treatment methods on the prognosis was compared. Kaplan-Meier method was used to draw the survival curve, Log rank test was used to analyze the survival difference of each group, and Cox proportional risk model was used to analyze the factors affecting the prognosis of patients with rectal mucinous adenocarcinoma.

Results

The overall survival (OS) rate of neoadjuvant radiotherapy was the highest, followed by postoperative radiotherapy, and finally by operation only, there were significant differences between each two groups (χ2=13.117, 22.541; P<0.05). However, the cancer-specific survival rate of the neoadjuvant chemoradiotherapy was significantly higher than that of postoperative radiotherapy (χ2=4.023, P=0.045). After propensity score matching for all data, the overall survival rate of neoadjuvant chemoradiotherapy was significantly higher than that of surgery only (χ2=4.874, P=0.027). The OS (χ2=5.530, P=0.019) and CSS (χ2=4.825, P=0.028) of non-elderly patients after surgery alone were significantly higher than those of postoperative radiotherapy. Elder (≥60 y), male, unchemotherapy, and high TNM stage are the influencing factors of poor OS of patients with rectal mucinous adenocarcinoma. Their HRs are 1.689 (95% CI=1.524~1.871), 1.110 (95% CI=1.007~1.223), 1.549 (95% CI=1.338~1.792), StageⅡ HR=2.675 (95% CI=1.191~6.008), StageⅢ HR=3.617 (95% CI=1.612~8.115), PhaseⅣ HR=10.835(95% CI=4.797~24.474); elder (≥60 y), unchemotherapy, and high TNM stage are the influencing factors of poor CSS in patients with rectal mucinous adenocarcinoma, and their HRs are 1.297 (95% CI=1.156~1.456), 1.344 (95% CI=1.129~1.601), stageⅢ HR=6.365 (95% CI=1.582~25.614), stageⅣ HR=20.957 (95% CI=5.189~84.637).

Conclusion

Elderly patients with rectal mucinous adenocarcinoma may benefit from neoadjuvant radiochemotherapy. For non-elderly patients, the prognosis of radiotherapy is not better than that of surgery alone.

表1 所有纳入研究的三组患者基线资料比较[例(%)]
图1 三种治疗方案的疗效比较。1A:三种治疗方案的总体生存率;1B:三种治疗方案的肿瘤特异性生存率
图2 年龄分层后三种治疗方案的生存率。2A:总体生存率;2B:肿瘤特异性生存率
图3 倾向得分匹配处理后不同年龄患者不同放疗时机的总体生存率。3A:老年组新辅助放疗和单纯手术比较;3B:老年术后放疗和单纯手术比较;3C:非老年组新辅助放疗和单纯手术比较;3D:非老年术后放疗和单纯手术比较
图4 倾向得分匹配处理后不同年龄患者不同放疗时机的肿瘤特异性生存率。4A:老年组新辅助放疗和单纯手术比较;4B:老年术后放疗和单纯手术比较;4C:非老年组新辅助放疗和单纯手术比较;4D:非老年术后放疗和单纯手术比较
表2 影响直肠黏液腺癌预后的COX多因素回归分析
[1]
中华人民共和国卫生和计划生育委员会医政医管局, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2017版)[J]. 中华胃肠外科杂志, 2018, 21(1): 92-106.
[2]
Sung H, Siegel RL, Rosenberg PS, et al. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry[J]. Lancet Public Health, 2019, 4(3): e137-e147.
[3]
Kang H, O′Connell JB, Maggard MA, et al. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum[J]. Dis Colon Rectum, 2005, 48(6): 1161-1168.
[4]
McCawley N, Clancy C, O′Neill BDP, et al. Mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: a systematic review and meta-analysis[J]. Dis Colon Rectum, 2016, 59(12): 1200-1208.
[5]
Kim TG, Park W, Choi DH, et al. Clinical significance of mucinous rectal adenocarcinoma following preoperative chemoradiotherapy and curative surgery[J]. Tumori, 2016, 102(1): 114-121.
[6]
Sengul N, Wexner SD, Woodhouse S, et al. Effects of radiotherapy on different histopathological types of rectal carcinoma[J]. Colorectal Dis, 2006, 8(4): 283-288.
[7]
Grillo-Ruggieri F, Mantello G, Berardi R, et al. Mucinous rectal adenocarcinoma can be associated to tumor downstaging after preoperative chemoradiotherapy[J]. Dis Colon Rectum, 2007, 50(10): 1594-1603.
[8]
Glynne-Jones R, Hall M. Radiotherapy and locally advanced rectal cancer[J]. Br J Surg, 2015, 102(12): 1443-1445.
[9]
Kakar S, Aksoy S, Burgart LJ, et al. Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival[J]. Mod Pathol, 2004, 17(6): 696-700.
[10]
Sengnl N, Wexner SD, Woodhouse S, et al. Effects of radiotherapy on different histopathologieal types of rectal carcinoma[J]. Colorectal Dis, 2006, 8(4): 283-288.
[11]
NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. Version 3.2017[EB/OL]. (2020-02-18).

URL    
[12]
Shahir MA, Lemmens VE, van de Poll-Franse LV, et al. Elderly patients with rectal cancer have a higher risk of treatment-related complications and a poorer prognosis than younger patients: A population-based study[J]. Eur J Cancer, 2006, 42(17): 3015-3021.
[13]
孙艳武, 池畔, 林惠铭, 等. 新辅助放化疗联合手术治疗直肠黏液腺癌的疗效分析[J]. 中华消化外科杂志, 2017, 16(1): 77-82.
[14]
Servagi VS, Guilbert P, Bouché G, et al. Hypofractionated radiotherapy in rectal cancer for elderly patients[J]. Cancer Radiother, 2018, 22(6-7): 644-646.
[15]
张悦仪, 王枭杰, 池畔, 等. 放疗联合手术治疗局部进展期直肠黏液腺癌的疗效分析:一项基于SEER数据库的回顾性研究[J]. 中华胃肠外科杂志, 2019, 22(1): 85-93.
[16]
Li Q, Li Y, Dai W, et al. Adjuvant radiotherapy improves cause specific survival in stage Ⅱ, not stage Ⅲ mucinous carcinoma of the rectum[J]. BMC Cancer, 2017, 17(1): 80.
[1] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[2] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[3] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[4] 张焱辉, 张蛟, 朱志贤. 留置肛管在中低位直肠癌新辅助放化疗后腹腔镜TME术中的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 25-28.
[5] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[6] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[7] 江振剑, 蒋明, 黄大莉. TK1、Ki67蛋白在分化型甲状腺癌组织中的表达及预后价值研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 623-626.
[8] 晏晴艳, 雍晓梅, 罗洪, 杜敏. 成都地区老年转移性乳腺癌的预后及生存因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 636-638.
[9] 鲁鑫, 许佳怡, 刘洋, 杨琴, 鞠雯雯, 徐缨龙. 早期LC术与PTCD续贯LC术治疗急性胆囊炎对患者肝功能及预后的影响比较[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 648-650.
[10] 钟广俊, 刘春华, 朱万森, 徐晓雷, 王兆军. MRI联合不同扫描序列在胃癌术前分期诊断及化疗效果和预后的评估[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 378-382.
[11] 胡宝茹, 尚乃舰, 高迪. 中晚期肝细胞癌的DCE-MRI及DWI表现与免疫治疗预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 399-403.
[12] 陆萍, 邹健. 凝血和纤维蛋白溶解标志物的动态变化对急性胰腺炎患者预后的评估价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 427-432.
[13] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[14] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[15] 索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.
阅读次数
全文


摘要